Concepedia

Author

Stefanie Jilg

Klinikum rechts der IsarORCID

Also Known As

Jilg, Stefanie, P Jost, S JILG, S Jilg, S. Jilg, Stefanie Jilg

39

Publications

698

Citations

10

H-Index

14

Concepts

All Affiliations

Klinikum rechts der IsarTechnical University of MunichGerman Cancer Research CenterHeidelberg UniversityPraxis für Hämatologie und Onkologie
SJ

About

Stefanie Jilg is an author at Klinikum rechts der Isar specializing in medicine, cell biology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

451

2

Cell Biology

3

3

451

3

Immunology

2

2

301

4

Health Sciences

1

1

103

5

Cancer Genetics

1

1

150

Stefanie Jilg

×

8

Publications

599

Citations

8

H-Index

YearCitations

RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells

Ulrike Höckendorf, Monica Yabal, Tobias Herold,

Cancer Cell

2016

198

Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms

Ashok Kumar Jayavelu, Tina M. Schnöder, Florian Perner,

Nature

2020

150

Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients

Stefanie Jilg, Veronika Reidel, Catharina Müller‐Thomas,

Leukemia

2015

103

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose

Stefanie Jilg, Richard Hauch, Johanna Kauschinger,

Experimental Hematology and Oncology

2019

40

Circulating <i>cKIT</i> and <i>PDGFRA</i> DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST)

Stefanie Jilg, Michael Rassner, Jacqueline Maier,

International Journal of Cancer

2019

33

How do Supervising Clinicians of a University Hospital and Associated Teaching Hospitals Rate the Relevance of the Key Competencies within the CanMEDS Roles Framework in Respect to Teaching in Clinical Clerkships?

Stefanie Jilg, Andreas Möltner, Pascal O. Berberat,

PubMed

2015

28

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM

Florian Huemer, Thomas Melchardt, Bettina Jansko,

European Journal Of Haematology

2019

26

Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile

Veronika Reidel, Johanna Kauschinger, Richard Hauch,

Oncotarget

2018

21

Page 1